↓ Skip to main content

Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy

Overview of attention for article published in Clinical Cancer Research, May 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Published in
Clinical Cancer Research, May 2015
DOI 10.1158/1078-0432.ccr-15-0363
Pubmed ID
Authors

Cooper, Zachary A, Reuben, Alexandre, Austin-Breneman, Jacob, Wargo, Jennifer A, Z. A. Cooper, A. Reuben, J. Austin-Breneman, J. A. Wargo

Abstract

BRAF inhibitor treatment (BRAFi) enhances anti-tumor immunity, but is associated with increased intra-tumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function, however recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Ecuador 1 3%
Unknown 36 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 39%
Other 6 16%
Student > Ph. D. Student 6 16%
Student > Bachelor 2 5%
Student > Master 2 5%
Other 2 5%
Unknown 5 13%
Readers by discipline Count As %
Medicine and Dentistry 9 24%
Biochemistry, Genetics and Molecular Biology 8 21%
Agricultural and Biological Sciences 4 11%
Chemistry 3 8%
Engineering 2 5%
Other 5 13%
Unknown 7 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2015.
All research outputs
#4,756,492
of 9,236,840 outputs
Outputs from Clinical Cancer Research
#3,732
of 5,926 outputs
Outputs of similar age
#113,437
of 224,855 outputs
Outputs of similar age from Clinical Cancer Research
#160
of 217 outputs
Altmetric has tracked 9,236,840 research outputs across all sources so far. This one is in the 45th percentile – i.e., 45% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,926 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 224,855 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 217 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.